EGP-437 (EyeGate Pharma), a corticosteroid formulation, was found to match the response rate to prednisolone acetate 1% for treatment of anterior uveitis.
Waltham, MA-In a phase III study, EGP-437 (EyeGate Pharma), a corticosteroid formulation, was found to match the response rate to prednisolone acetate 1%, the current standard of care for treatment of anterior uveitis.
EGP-437 was administered in two iontophoretic treatments on two separate days, in contrast to prednisolone, which was administered as multiple daily eyedrops.
Regarding safety, the incidence and severity of treatment-emergent adverse events in both groups were comparable and there were fewer incidences of elevated IOP in the EGP-437 group.
“Inadequate compliance with aggressive eye drop regimens often leads to treatment failures,” said John Sheppard, MD, the studyÊ¼s principal investigator. “Offering our [patients with uveitis] a safe, effective treatment option that is controlled by the healthcare provider rather than the patient represents an important breakthrough.”
“This is a major milestone for the company and the ophthalmology sector as it further validates a unique new way to deliver therapeutics into the eye,” said Stephen From, president and chief executive officer of EyeGate Pharma. “Treating uveitis requires up to 16 eyedrops per day over a period of 4 to 6 weeks, which is very inconvenient for the patient. A couple of treatments with our product produced the same results, which is much simpler and more reliable for the patient.”
For more articles in this issue of Ophthalmology Times eReport, click here.